The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing.
Cells
; 10(11)2021 11 02.
Article
in English
| MEDLINE | ID: covidwho-1533813
ABSTRACT
Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory conditions have highlighted the significant benefit to patients who respond to MSC administration. Thus, there is strong interest in investigating MSC therapy in acute inflammatory lung conditions, such as acute respiratory distress syndrome (ARDS). Unfortunately, not all patients respond, and evidence now suggests that the differential disease microenvironment present across patients and sub-phenotypes of disease or across disease severities influences MSC licensing, function and therapeutic efficacy. Here, we discuss the importance of licensing MSCs and the need to better understand how the disease microenvironment influences MSC activation and therapeutic actions, in addition to the need for a patient-stratification approach.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Mesenchymal Stem Cells
/
Inflammation
/
Lung
Type of study:
Prognostic study
Limits:
Animals
/
Humans
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Cells10112982
Similar
MEDLINE
...
LILACS
LIS